Altrius Capital Management Inc Has $6.93 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Altrius Capital Management Inc reduced its position in AstraZeneca PLC (NASDAQ:AZN) by 0.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 96,858 shares of the company’s stock after selling 305 shares during the quarter. AstraZeneca makes up about 2.1% of Altrius Capital Management Inc’s portfolio, making the stock its 11th largest position. Altrius Capital Management Inc’s holdings in AstraZeneca were worth $6,932,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the company. Aspire Private Capital LLC purchased a new position in AstraZeneca during the 1st quarter worth $17,491,320,000. ICA Group Wealth Management LLC bought a new stake in shares of AstraZeneca in the fourth quarter valued at approximately $26,000. Parkside Financial Bank & Trust raised its holdings in AstraZeneca by 4,875.0% during the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after acquiring an additional 390 shares during the period. Fairfield Bush & CO. purchased a new stake in AstraZeneca during the 1st quarter worth about $28,000. Finally, Syverson Strege & Co purchased a new stake in shares of AstraZeneca in the first quarter worth about $30,000. 15.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Erste Group Bank restated a “hold” rating on shares of AstraZeneca in a research report on Friday, September 8th. StockNews.com began coverage on shares of AstraZeneca in a research note on Thursday, October 5th. They issued a “strong-buy” rating on the stock. Finally, Jefferies Financial Group raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Monday, September 25th. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $103.00.

AstraZeneca Price Performance

Shares of AstraZeneca stock traded down $0.43 during trading on Monday, hitting $63.70. 1,831,630 shares of the stock traded hands, compared to its average volume of 5,026,677. The firm’s fifty day moving average is $65.77 and its 200-day moving average is $68.96. The stock has a market cap of $197.46 billion, a price-to-earnings ratio of 33.56, a PEG ratio of 1.28 and a beta of 0.51. AstraZeneca PLC has a 52 week low of $61.73 and a 52 week high of $76.56. The company has a quick ratio of 0.60, a current ratio of 0.79 and a debt-to-equity ratio of 0.60.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.84 by $0.03. AstraZeneca had a net margin of 13.10% and a return on equity of 30.30%. The firm had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same period last year, the firm posted $0.84 earnings per share. The business’s revenue was up 4.6% compared to the same quarter last year. Research analysts expect that AstraZeneca PLC will post 3.64 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.